



Notification 6406

Implementation Date

10/5/2023

Category

HCPCS - Drugs & Biologicals

Topic

LA Medicaid – Injection, vedolizumab, 1 mg

What is changing?

We limit reimbursement of charges for vedolizumab, 1 mg, to claims submitted with 1 of the following diagnoses:

- Ulcerative colitis
- Crohn's disease

Language

English

Impacted Products

- Medicaid – Louisiana

Why is Humana making this change?

According to the FDA-approved package insert and prescribing information, vedolizumab is an integrin receptor antagonist indicated in adults for the treatment of moderately to severely active ulcerative colitis and moderate to severe active Crohn's disease.